ATS 2024 Final Program

Click on the session title to view the speakers

176

MONDAY • MAY 20

P299 Peroxidase-mediated Mucin Cross-linking Explains Pathologic Mucus Gel Formation in IL-13-stimulated Airway Epithelial Cells P300 Severe Asthmatic Human Airway Epithelial Cells (HAECs) Exhibit Differential Viral-Related Immune Responses Under Type-2 (T2) Conditions P301 Glycolysis of Airway Fibroblasts Fuels Severe Asthma Phenotype P302 Rhinovirus (RV) Utilizes T2-induced Mitophagy to Increase Early RV Replication in Human Airway Epithelial Cells P303 Intersecting Pathways of Metabolic Dysregulation and GLP-1 Receptor Agonist Effects in Airway Smooth Muscle Cells P304 Anti-Interleukin-4 Receptor Subunit Alpha Antibody M1 Reduces Pulmonary Inflammation in Mouse Ovalbumin Model of Asthma P305 Rhinovirus C15 Induces Epithelial Remodeling and Inflammatory Cytokine Expression: Implications for Asthma Exacerbation P306 IL-13 and IL-17A Activate ß1 Integrins Through an NF- k B/Rho Kinase/PIP5K1 g Pathway to Enhance Force Transmission in Airway Smooth Muscle P307 The Regulatory Mechanism of Membrane-bound Mucins in Normal Human Bronchial Epithelial Cells P308 Investigation of the Mechanism Underlying the Bronchoprotective Effect of Deep Inspiration P309 Lung-targeted RNAi Molecules Silence Human TSLP Expression in PCLS Cultures and Humanized Mice and Suppress Pulmonary Allergic Inflammation P310 Clinically Relevant ß2-agonists Induce and Augment Rhinovirus-induction of Asthma-relevant Pro-inflammatory Mediators in Human Bronchial Epithelial Cells P311 GDC-0214 Is a Potent Inhaled JAK Inhibitor With Efficacy in Multiple Pre-clinical Models of Th2 Inflammation: A Perspective on Use of In Vivo Rodent Models for Early Phase Drug Discovery P312 Cannabinoid Receptor 1 Inverse Agonist, INV-202, Increases Surfactant Phosphatidylcholines and Improves Lung Compliance in a Mouse Model of Asthma

BASIC • TRANSLATIONAL THEMATIC POSTER SESSION

B72 LUNG INFECTIONS AND COVID-19: INSIGHTS, INNOVATIONS, AND IMPACT 9:15 a.m. - 4:15 p.m. Viewing: Posters will be on display for entire session Discussion: 11:30-12:30 Discussionwith facilitators, authors, andattendees 12:30-1:15 Authorswill beby their posters for individual discussionwithattendees P1011 Evaluation of Targeted Delivery of Specific Antisense Oligonucleotides Via Engineered Exosomes to Combat COVID-19 Disease Using Human Airway Epithelial Cultures P1012 SARS-CoV-2 Spike Transfection Impairs Airway Epithelial Repair P1013 Investigating the Toll-like Receptor 3 (TLR3) Leu412phe (TLR3 L412F) Single Nucleotide Polymorphism in the Pathogenesis of Long COVID P1014 PTP4A3 Inhibitors Ameliorate SARS-CoV-2-related ARDS by Stimulating Alcohol Metabolism P1015 Developing a Novel Therapeutic for Smokers Infected With SARS-CoV-2 P1016 CITE-Seq Analysis Reveals Responses in Resident Pulmonary Immune Cells Following SARS-CoV-2 Infection P1017 Actin Fence Therapy Against COVID-19 P1018 Plasma Levels of Surfactant Protein D Support the Interpretation of Oxygenation Parameters in COVID-19 Patients With ARDS. P1019 RNase6 Promotes Stress-induced Translational Repression During Bacterial Infection P1020 Distinct Alveolar and Bone-Marrow Derived Macrophages Signatures After Bacterial Challenge P1021 Induction of Lung Epithelial Antimicrobial Hypoxia-inducible Factor1 a Signaling by Temporal Immunometabolic Shift to Aerobic Glycolysis P1022 Regulatory T Cell-dependent Resolution of Pneumonia Requires DHX58-DEC2-GATA3 San Diego Convention Center Area I (Hall H, Ground Level)

ATS 2024 Conference Program • San Diego, CA